Metastatic Colorectal cancer - Pipeline Insight, 2022
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Metastatic Colorectal cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in Metastatic Colorectal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Metastatic Colorectal cancer: Overview
Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor. CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer is the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. Approximately one-fifth of CRC cases are metastatic at the time of diagnosis. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC. Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is. There are different types of polyps.
'Metastatic Colorectal cancer - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Colorectal cancer pipeline landscape is provided which includes the disease overview and Metastatic Colorectal cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Colorectal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Metastatic Colorectal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Metastatic Colorectal cancer Emerging Drugs
It is a novel therapeutic approach, which is given before chemotherapy that temporarily blocks progression through the cell cycle. This provides two benefits. First, it proactively helps protect HSPCs in bone marrow leading to preservation of neutrophils, erythrocytes, and platelets (called myeloprotection) which reduces the occurrences and severity of neutropenia and other myelosuppressive consequences of chemotherapy.
Further product details are provided in the report……..
Metastatic Colorectal cancer: Therapeutic Assessment
This segment of the report provides insights about the different Metastatic Colorectal cancer drugs segregated based on following parameters that define the scope of the report, such as:
Metastatic Colorectal cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Colorectal cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Colorectal cancer drugs.
Metastatic Colorectal cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Metastatic Colorectal cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in Metastatic Colorectal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Metastatic Colorectal cancer: Overview
Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor. CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer is the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. Approximately one-fifth of CRC cases are metastatic at the time of diagnosis. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC. Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is. There are different types of polyps.
'Metastatic Colorectal cancer - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Colorectal cancer pipeline landscape is provided which includes the disease overview and Metastatic Colorectal cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Colorectal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Colorectal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Colorectal cancer.
- On November 18, 2021 Gilead Sciences announced that it had exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat. The two companies have also added a research collaboration deal. Arcus shares popped 15% at the news.
- In September 2021, Erasca, announced a clinical trial collaboration and supply agreement with Pfizer Inc. for the BRAF inhibitor encorafenib (BRAFTOVI®). This agreement will support a clinical proof-of-concept study evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E-mutant mCRC.
- In December 2021, Rottapharm Biotech announced a clinical collaboration with Agenus’ balstilimab (anti-PD-1) in collaboration with its lead candidate CR6086 in advanced colorectal cancer at the National Cancer Institute. Rottapharm Biotech’s clinical collaboration with Agenus offers a promising new combination therapy for patients with advanced pMMR/MSS mCRC where there is a high unmet need, and for a further range of potential applications in other immunotherapy-resistant tumors.
- On 11 May 2021, Shanghai Henlius Biotech and NeuPharma entered into a drug technology license agreement. NeuPharma will grant the Company a sublicensable exclusive license for related licensed patents and licensed know-how necessary or reasonably useful for the Company to research, develop, produce and commercialize the Licensed Product within the Licensed Territory (China).
- In November 2021, The US FDA granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC). This serves as a strong external validation of arfolitixorin’s potential to benefit patients with this devastating disease.
- In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.
This segment of the Metastatic Colorectal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Metastatic Colorectal cancer Emerging Drugs
- Trilaciclib: G1 Therapeutics
It is a novel therapeutic approach, which is given before chemotherapy that temporarily blocks progression through the cell cycle. This provides two benefits. First, it proactively helps protect HSPCs in bone marrow leading to preservation of neutrophils, erythrocytes, and platelets (called myeloprotection) which reduces the occurrences and severity of neutropenia and other myelosuppressive consequences of chemotherapy.
- Famitinib: Jiangsu Hengrui Medicine
- CMAB009: Mabpharm Limitied
- Trastuzumab Deruxtecan: Daiichi Sankyo
- SCO-101: Scandion Oncology
- BEY 1107: BeyondBio
- Etrumadenant: Arcus Biosciences
Further product details are provided in the report……..
Metastatic Colorectal cancer: Therapeutic Assessment
This segment of the report provides insights about the different Metastatic Colorectal cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Metastatic Colorectal cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intradermal
- Intradermal/Intratumoral/Intravenous
- Intrahepatic arterial (IHA)
- Intralesional
- Intramuscular
- Intratumoural
- Intravenous
- Oral
- Oral/Intravenous
- Parenteral
- Subcutaneous
- Molecule Type
- Gene therapies
- Immunotherapies
- Monoclonal antibodies
- Recombinant Fusion Proteins
- Small molecule
- Vaccine
- Product Type
Metastatic Colorectal cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Colorectal cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Colorectal cancer drugs.
Metastatic Colorectal cancer Report Insights
- Metastatic Colorectal cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Metastatic Colorectal cancer drugs?
- How many Metastatic Colorectal cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Colorectal cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Colorectal cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Metastatic Colorectal cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- G1 Therapeutics
- Amgen
- Qilu Pharmaceutical
- Eisai Co Ltd
- Merck Sharp & Dohme
- Mirati Therapeutics
- Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
- Shanghai Henlius Biotech
- Amarin Corporation
- Mologen
- Sumitomo Dainippon Pharma Oncology
- Celltrion
- Merck Sharp & Dohme
- Jiangsu Hengrui Medicine
- Suzhou Zelgen Biopharmaceuticals
- Mabpharm Limitied
- Boehringer Ingelheim
- Chia Tai Tianqing Pharmaceutical
- Isofol Medical
- Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine
- AB Science
- Gritstone Bio, Inc
- Daiichi Sankyo
- Novartis
- Merck Sharp & Dohme
- Sunshine Guojian Pharmaceutical
- Pfizer
- Merck KGaA
- Jiangsu HengRui Medicine Co., Ltd.
- ALX Oncology
- Immunovative Therapies
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Precision Biologics
- Sanofi
- GC Pharma
- VAXIMM
- AstraZeneca
- AstraZeneca
- Yooyoung Pharmaceutical
- Med Pacto Inc.
- Exelixis
- GlaxoSmithKline
- Bristol Myers Squibb
- Merck Sharp & Dohme
- Bavarian Nordic
- Maxinovel Pharmaceuticals
- Shanghai Henlius Biotech
- Novartis
- Zucero Therapeutics
- Innovent Biologics
- Scandion Oncology
- Merck Sharp & Dohme Corp.
- AbbVie
- Beijing Biostar Technologies
- Seagen Inc
- Merck KGaA
- Teclison Ltd
- Symphogen A/S
- Sichuan Baili Pharmaceutical; SystImmune
- Karyopharm Therapeutics
- Trilaciclib
- Sotorasib
- QL 1203
- Lenvatinib
- Olaparib
- MRTX 849
- KL 140
- HLX10 (Serplulimab) + HLX04
- Icosapent Ethyl
- MGN-1703
- Napabucasin
- CT-P16
- MK-4280A
- Famitinib
- Donafenib
- CMAB009
- BI 695502
- Anlotinib hydrochloride
- Arfolitixorin
- SHR 1701
- Masitinib
- GRT C901/GRT R902
- Trastuzumab deruxtecan
- Dabrafenib+ Trametinib
- GVAX Colon Vaccine
- CPGJ 602
- Axitinib
- Avelumab
- Apatinib
- ALX-148
- AlloStim
- AK 105
- NEO-102
- Isatuximab
- GC 1118
- 'VXM 01
- Durvalumab
- Tremelimumab
- YYB101
- Vactosertib
- Cabozantinib
- Niraparib
- Neoantigen Dendritic Cell Vaccine
- Navarixin
- CV301
- MAX-40279-01
- HLX208
- NIS793
- Pixatimod
- IBI310
- SCO-101
- Vicriviroc
- Veliparib
- Utidelone
- Tucatinib
- Tepotinib
- TATE
- Sym004
- SI-B001
- Selinexor
Introduction
Executive Summary
Metastatic Colorectal cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Metastatic Colorectal cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Trilaciclib: G1 Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
SHR 1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Trastuzumab Deruxtecan: Daiichi Sankyo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
NKTR-255: Nektar Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Talimogene Laherparepvec: Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
PCS11T: Processa Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Metastatic Colorectal cancer Key Companies
Metastatic Colorectal cancer Key Products
Metastatic Colorectal cancer- Unmet Needs
Metastatic Colorectal cancer- Market Drivers and Barriers
Metastatic Colorectal cancer- Future Perspectives and Conclusion
Metastatic Colorectal cancer Analyst Views
Metastatic Colorectal cancer Key Companies
Appendix
Executive Summary
Metastatic Colorectal cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Metastatic Colorectal cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Trilaciclib: G1 Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
SHR 1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Trastuzumab Deruxtecan: Daiichi Sankyo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
NKTR-255: Nektar Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Talimogene Laherparepvec: Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
PCS11T: Processa Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Metastatic Colorectal cancer Key Companies
Metastatic Colorectal cancer Key Products
Metastatic Colorectal cancer- Unmet Needs
Metastatic Colorectal cancer- Market Drivers and Barriers
Metastatic Colorectal cancer- Future Perspectives and Conclusion
Metastatic Colorectal cancer Analyst Views
Metastatic Colorectal cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Metastatic Colorectal cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Metastatic Colorectal cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Metastatic Colorectal cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Metastatic Colorectal cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
